![]()
A Food and Drug Administration advisory panel voted unanimously Wednesday to recommend approval for GlaxoSmithKline's new drug candidate Shingrix, a vaccine for preventing shingles in adults age 50 and older.
The vote by the Vaccines and Related Biological Products Advisory Committee was 11-0 in support of the biologics license application submitted by GlaxoSmithKline last October. The committee's recommendation is nonbinding, but the FDA typically follows the advice of its advisory panels.
If…